ALEXION PHARMACEUTICALS, INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
A Prospective Sub-Study of the Global Hypophosphatasia Registry
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05234567
- Locations
- πΊπΈ
Clinical Trial Site, Madison, Wisconsin, United States
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05218096
- Locations
- π¨π³
Research Site, Taoyuan City, Taiwan
Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT05202145
- Locations
- πΊπΈ
Clinical Study Site, Tempe, Arizona, United States
A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT05109390
- Locations
- πΊπΈ
Clinical Trial Site, Tempe, Arizona, United States
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT05097989
- Locations
- π¬π§
Research Site, Newcastle upon Tyne, United Kingdom
A Study of Single-dose ALXN2050 in Healthy Adults
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05047458
- Locations
- π³πΏ
Clinical Trial Site, Auckland, New Zealand
A Study of Multiple Doses of ALXN2050 in Healthy Adults
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05047484
- Locations
- π³πΏ
Clinical Trial Site, Auckland, New Zealand
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05047523
- Locations
- πͺπΈ
Research Site, Pamplona, Spain
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT05019521
- Locations
- π¬π§
Research Site, Southampton, United Kingdom
A Study of the Cardiac Effects of Danicopan in Healthy Adults
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT05016206
- Locations
- πΊπΈ
Clinical Trial Site, Tempe, Arizona, United States
Β© Copyright 2024. All Rights Reserved by MedPath